Pipeline

Focused on the Future

Our robust pipeline is strategically diversified across several therapeutic areas in ophthalmology that represent attractive market opportunities and continued growth potential. Our product candidates are engineered to address specific therapeutic needs across ocular surface, anterior segment and posterior segment diseases, including the leading causes of blindness. With an aging population, there is a clear growing need for these types of innovative ocular therapies that may enhance the overall patient and physician experience.

Program Therapeutic Focus Preclinical Early/Mid Clinical Stage (Phase 1 – Phase 2) Pivotal Clinical Trial Stage (Phase 3) FDA Approval Current Status / Anticipated Milestones
Program

(axitinib intravitreal implant)

Therapeutic Focus
Wet AMD*
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Pivotal Clinical Trial Stage (Phase 3)
Current Status / Anticipated Milestones
Enrolling patients in SOL-1 trial
Program

AXPAXLI
(axitinib intravitreal implant)

Therapeutic Focus
Diabetic Retinopathy
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Current Status / Anticipated Milestones
Presented Phase 1 HELIOS results in NPDR
Program

(travoprost intracameral implant)

Therapeutic Focus
Glaucoma and ocular hypertension
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Current Status / Anticipated Milestones
Presented top-line data from Phase 2 trial in glaucoma

Program

Therapeutic Focus
Post surgical ocular inflammation and pain
Ocular itching associated with allergic conjunctivitis
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Pivotal Clinical Trial Stage (Phase 3)
FDA Approval
Current Status / Anticipated Milestones
Nearly 400,000 eyes treated to date
2023 Achieved $57.9M in net product revenue

* Age-related Macular Degeneration (AMD)

†AXPAXLITM (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI

PAXTRAVATM (travoprost intracameral implant), also referenced as laboratory code OTX-TIC

Caution: All investigational product candidates are currently undergoing clinical evaluation. This chart is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval.

Learn more about our FDA-approved products